Phase 2 Retina Clinical Trials
24 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 24 trials
Recruiting
Phase 1Phase 2
Disulfiram for Treatment of Retinal Degeneration
Inherited Retinal Dystrophy Primarily Involving Sensory Retina
University of Washington30 enrolled1 locationNCT05626920
Recruiting
Phase 1Phase 2
Oral Metformin for Treatment of ABCA4 Retinopathy
Retinal DegenerationRetinal DystrophyStargardt Disease+1 more
National Eye Institute (NEI)56 enrolled2 locationsNCT04545736
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
Retinitis pigmentosa (RP)Retinal DegenerationPrimary Photoreceptor Disease+6 more
BlueRock Therapeutics54 enrolled4 locationsNCT06789445
Recruiting
Phase 2
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
deaf-blindRetinitis pigmentosa (RP)Retinal Disease+4 more
Laboratoires Thea81 enrolled27 locationsNCT06627179
Recruiting
Phase 2
SGLT2 Inhibitors in Geographic Atrophy
Geographic AtrophyRetinal diseasesRetinal Degeneration+2 more
Washington University School of Medicine70 enrolled1 locationNCT07174687
Recruiting
Phase 1Phase 2
Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)
Retinal Dystrophy Due to Biallelic ABCA4 MutationsStargardt Disease 1
VeonGen Therapeutics GmbH15 enrolled1 locationNCT07002398
Recruiting
Phase 2
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
Non-Proliferative Diabetic RetinopathyRetinal Vein Occlusion
Annexin Pharmaceuticals AB12 enrolled1 locationNCT07259928
Recruiting
Phase 1Phase 2
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
Retinal DegenerationRetinal DiseaseRetinal Dystrophies+2 more
PYC Therapeutics16 enrolled6 locationsNCT06852963
Recruiting
Phase 2
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
Neovascular Age-Related Macular Degeneration (NVAMD)Branch Retinal Vein Occlusion (BRVO)
EyeBiotech Ltd.160 enrolled49 locationsNCT07205887
Recruiting
Phase 1Phase 2
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
Retinitis PigmentosaChoroideremiaNon-Syndromic Rod-Dominant Inherited Retinal Diseases
Kiora Pharmaceuticals, Inc.48 enrolled3 locationsNCT05282953
Recruiting
Phase 1Phase 2
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
rhegmatogenous retinal detachmentProliferative Vitreoretinopathy
Massachusetts Eye and Ear Infirmary48 enrolled1 locationNCT06033703
Recruiting
Phase 2
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
Von Hippel-Lindau DiseasePheochromocytoma/ParagangliomaVon Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma+5 more
José Claudio Casali da Rocha100 enrolled1 locationNCT07167329
Recruiting
Phase 2
Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
Unity Health Toronto50 enrolled2 locationsNCT05523869
Recruiting
Phase 1Phase 2
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
Geographic AtrophyAge-Related Macular DegenerationMacular Degeneration+2 more
Eyestem Research Pvt. Ltd.54 enrolled3 locationsNCT06394232
Recruiting
Phase 1Phase 2
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
Leber Congenital AmaurosisInherited Retinal Diseases Caused by RPE65 Mutations
HuidaGene Therapeutics Co., Ltd.20 enrolled3 locationsNCT05906953
Recruiting
Phase 2Phase 3
Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin
Diabetic Macular EdemaMacular EdemaRetinal Neovascularization
Isfahan University of Medical Sciences52 enrolled1 locationNCT06595355
Recruiting
Phase 2
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
rhegmatogenous retinal detachmentProliferative Vitreoretinopathy
Cincinnati Eye Institute, Southwest Ohio860 enrolled1 locationNCT06541574
Recruiting
Phase 1Phase 2
Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy
Biallelic RPE65 Mutation-associated Retinal Dystrophy
Frontera Therapeutics9 enrolled1 locationNCT05858983
Recruiting
Phase 1Phase 2
Minocycline for Chronic Autoimmune Uveitis
MinocyclineUveitisRetinal Degeneration
Sun Yat-sen University10 enrolled1 locationNCT05474729
Completed
Phase 2
Safety and efficacy of intra-vitreal bevacizumab combined with supra-choroidal triamcinolone in the treatment of central retinal vein occlusion.
Central retinal vein occlusion
Salahuddin34 enrolled1 locationACTRN12622000267752